MannKind Corporation announced a $50 million private placement led by Frazier Life Sciences, selling common stock and pre-funded warrants to institutional investors. The funds will support general corporate purposes, including a $45 million payment linked to the recent FDA approval of their drug Furoscix ReadyFlow™, an autoinjector for treating edema in heart failure and chronic kidney disease. The financing is expected to close around July 24, 2026, and MannKind plans to register the resale of these securities with the SEC. This capital raise aims to strengthen MannKind's position as it advances treatments for cardiometabolic and orphan lung diseases.
BiomX's subsidiary Zorronet has partnered with Czech company Samura s.r.o. to expand its AI-powered monitoring technology across Central and Eastern Europe. The collaborations focus on smart pest management in agriculture and protecting critical tran...
EquipmentShare.com Inc. and some executives face a securities fraud lawsuit alleging they misled investors by not disclosing ongoing related-party transactions after their January 2026 IPO. The complaint claims founder-related entities continued undi...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share transactions on July 23, 2026. The bank purchased 640,099 ordinary shares at prices between 280 and 280.25 per unit and sold 650,000 sh...
SAP reported strong Q2 results, beating GAAP EPS estimates and maintaining over 20% growth in cloud revenue. Despite a 40% drop in share price this year, the company shows operational strength and expects revenue acceleration by 2027. The resilience ...
Opawica Explorations Inc. announced a non-brokered private placement to raise up to CAD $1.5 million by issuing 15 million units at $0.10 each. Each unit includes one common share and half a warrant, exercisable at $0.20 within 24 months. The funds w...
